DOCSLIB.ORG

Tot-JNK 18S Patent Application Publication Mar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tot-JNK 18S Patent Application Publication Mar US 2010.0075894A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0075894 A1 Hotamisligil et al. (43) Pub. Date: Mar. 25, 2010 (54) REDUCINGER STRESS IN THE TREATMENT A63L/92 (2006.01) OF OBESITY AND DABETES A 6LX 3/575 (2006.01) A63/04 (2006.01) (75) Inventors: Gökhan S. Hotamisligil, Wellesley, A6II 3/55 (2006.01) MA (US); Umut Ozcan, Brookline, A613/60 (2006.01) MA (US) A6IP3/10 (2006.01) A6IP3/04 (2006.01) Correspondence Address: A6IP 9/10 (2006.01) EDWARDSANGELL PALMER & DODGE LLP (s2 usic... 514/4; 435/7.2:436/86; 514/570; P.O. BOX SS874 514/169; 514/740: 514/171; 514/635: 514/165 BOSTON, MA 02205 (US) (57) ABSTRACT (73) Assignee: HARYARPN.YERSITY, Endoplasmic reticulum stress has been found to be associated ambridge, (US) with obesity. Therefore, agents that reduce or prevent ER (21) Appl. No.: 12/541,020 stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and (22) Filed: Aug. 13, 2009 type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include Related U.S. Application Data 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other (63) Continuation of application No. 1 1/227.497, filed on compounds useful in reducing ER stress are chemical chap Sep. 15, 2005, now abandoned. erones Such as trimethylamine N-oxide and glycerol. The (60) Provisional application No. 60/610,093, filed on Sep. E. invention provides methods of treating a subject suf 15, 2004. ering from obesity, hyperglycemia, type 2 diabetes, or insu s lin resistance using ER stress reducers such as PBA, TUDCA, O O and TMAO. Methods of screening for ER stress reducers by Publication Classification identifying agents that reduce levels of ER stress markers in (51) Int. Cl. ER stressed cells are also provided. These agents may find use A6 IK 38/28 (2006.01) in methods and pharmaceutical compositions for treating GOIN 33/53 (2006.01) obesity-associated diseases. LEAN Ob/Ob RD HFD 3. sik--XBP-1(S) GRP78 28S 18S LEAN Ob/Ob IGRP78 28S --Tot-JNK 18S Patent Application Publication Mar. 25, 2010 Sheet 1 of 22 US 2010/0075894 A1 qO/GO qO/qONWET Patent Application Publication Mar. 25, 2010 Sheet 2 of 22 US 2010/0075894 A1 IP: IRS-1 E. E.s R.ss IB:IP: IRS-1IRS-1 ser307 IB: IRS-1 ser307 AIP: IRS-1 IP: IRS-1 EgySESSIB: IRS-1 EIB. IRS-1 IP: pY IB: IRS-1 IP: pY IB: pY Patent Application Publication Mar. 25, 2010 Sheet 3 of 22 US 2010/0075894 A1 is is 2,: ESSEEE i E.SR g Tot-JNK O 1 h FIG. 3A Tun: IP: IRS-1 s IB: p-IRS-1Ser307 IP: IRS-1 *." IB: IRS-1 IB: p-IRS-1 ser307 IP: IRS-1 IB: IRS-1 Patent Application Publication Mar. 25, 2010 Sheet 4 of 22 US 2010/0075894 A1 IRE-1Ot/ IRE-1O/ Ins: - - - - - - - - - - - - - - IP: IRS-1 IB: pY IP: IRS B: IRS-1 N - DIRE-1 +/- 5g.DN OIRE-1 -/- O.8 25U. 0.4 O.O Patent Application Publication Mar. 25, 2010 Sheet 5 of 22 US 2010/0075894 A1 3OO U) g 250 c 3 S. S 2 15O O Ye - O 1OO nS 5O O X PBS 4-PBA FIG. 4A 350 300 g a 250 - O3 N.G 200 t5 a1E 150 g 1OO O O 15 3O 6O 90 12O Minutes After Insulin Injection FIG. 4B Patent Application Publication Mar. 25, 2010 Sheet 6 of 22 US 2010/0075894 A1 Body Weight During Trial ex - - - - - - - - - - - - - - - - - - - V - - - ----------------------a ma ------mava --- m V-w 500 OO S. 50.00 ... -- ob/ob PBS si cleanPBS Eg 40.00-TV. to -A--- ob/oblean PBS PBA 3350- 300 His ean PBA g 30.00 * -e- lean PBA S 58 & 20.00 ---------r 3 ra 15 & 10.00 as 19 O.OO 8 R O Day 0 Day 20 S S R Days A FIG. 5B so. ITT at 15th day. Insulin Levels i 300 14 s -s 12 ob/ob PBS is 250 510 Zob/ob PBA 200- -- ob/ob pbs S. Olean PBS Ne -- ob/ob pba S 8 Sean PBA S; 150 -A-lean pbs 6 8 100 r-e-lean pba 4 5 50 - 2 8 O O i O 30 60 90 120 Minutes After Insulin Injection FIG. 5D Patent Application Publication Mar. 25, 2010 Sheet 7 of 22 US 2010/0075894 A1 Blood Glucose Levels ob/ob(PBS) 4 O O ob/ob(TUD) O Lean (PBS) Lean (TUD) 2 O O 54O ckk ck k ck >k 450 KK ck k ckk -- ob/ob (TUDCA) 36O -H ob/ob (PBS) -A- Lean (PBS) 27O -X - Lean (TUDCA) 18O 9 O O O 15 3O 60 90 120 Minutes After Insulin Injection FIG. 6B Patent Application Publication Mar. 25, 2010 Sheet 8 of 22 US 2010/0075894 A1 5OO 400 3OO 2OO 1OO Days of treatment of diabetic mice with TMAO FIG. 7A 16. O PBS OTMAO S. 12.. O - s 8. O O39 Na Days of treatment of diabetic mice with TMAO FIG. 7B Patent Application Publication Mar. 25, 2010 Sheet 9 of 22 US 2010/0075894 A1 6 O O 3O O 200 1 OO O PBS PBA (200mg) MET (200mg) PBA--MET (200) Treatment (diabetic mice, ob/ob, treated for 11 days at 200 mg/kg/day dose) Glu (mM) STZ. al -- O 5 10 25 75 var-Y mall GRP78 sausales as 28s is 18S Patent Application Publication Mar. 25, 2010 Sheet 10 of 22 US 2010/0075894 A1 FIG. 1 OA Lean Ob/Ob Patent Application Publication Mar. 25, 2010 Sheet 11 of 22 US 2010/0075894 A1 IB: pY : IB: IRS-1Pser a , IP: IRS-1 s IB : IRS-1 Control Insulin s O Ins+Tun O 1OO 200 Phospho/Total ?yS 200 k IP: IRS-1 IB: IRS-1Pser 'g. 120 s IP: IRS-1 th 40 IB: IRS-1 Thap: - - + + JNKi: - - - - IP: pY IB: IRS-1 .. IP: pY IB: pY Patent Application Publication Mar. 25, 2010 Sheet 12 of 22 US 2010/0075894 A1 TUn: - -- -- -- Time(hr): O 1. 2 4 p-c-Jun - IP: IRS-1 : IB: IRS-1 pSer307 IP: IRS-1 IB: IRS-1 p-c-Jun s IP: IRS-1 IB: IRS-1 pSer307 IP: IRS-1 IB: IRS-1 IRE-1Ot/ IRE-O/ Tun; O O 1 2 3 4 O O 1 2 3 4 (hr) Ins: - - - - IP: IRS-1 IB; pY IP: IRS-1 IB: IRS-1 5OO IRE1 -/- k 4OO IRE-1 - A.A -- 3OO i 2OO 1OO Tun: O O 1. 2 3 4 (hr) Ins: - H -- -- -- -- FIG. 11H Patent Application Publication Mar. 25, 2010 Sheet 13 of 22 US 2010/0075894 A1 : IRS-1 : pY : IRS-1 : IRS-1 pSer307 : IRS-1 : IRS-1 IR : pY : IR : IR IP: IRS-1 IB: IRS-1 pSer307 IP: IRS-1 IB : IRS-1 FIG. 12B Patent Application Publication Mar. 25, 2010 Sheet 14 of 22 US 2010/0075894 A1 - FDOX- -DOX Tun(2g/ml): - + + + + + - + + + + + Time(hr): O 1 2 3 4 5 O 1 2 3 4 5 FIG. 13A --DOX -DOx Tun (2ug/ml): - + + + + + + - + + + + + + Time(hr): O 0.51 2 3 4 5 O 0.51 2 3 4 5 : - - JNK FIG. 13C XBP-1/ XBP-t/- Tun(O.5ug/ml): - + + + + + + - + + + + + + Time(hr): O O.5 1 2 3 4 5 O 0.51 2 3 4 5 FIG. 13D Patent Application Publication Mar. 25, 2010 Sheet 15 of 22 US 2010/0075894 A1 --DOX -DOX Tun (2g/ml): - + + - - - -- Time(hr): O 4 5 O 4 5 S 1000 D-Dox Y pSer307 '3. 600 ", 400 U?) St IRS-1 a 200 FIG 13E Time(hr): O +Dox 500 400 Uh 300 9, 200 1OO i Time(hr): 5 Tun: - -H Ins: - H XBP-1-/- XBP-1t/t EXBP-1 -/- N Tun (O.5ug/ml): - + + - + + O 2500 XBP-1 /+ Time(hr): O 4 5 O 4 5 8 2000 w IRS-1 S. 15OO H OOO U : g 5OO Time(hr): O 4 5 Tun: - -- -- Ins: - -- -- FIG. 13H Patent Application Publication Mar. 25, 2010 Sheet 16 of 22 US 2010/0075894 A1 --Dox -DOX Tun (2g/ml): O O 0.5 1 2 3 4 O O 0.5 1 2 3 4 (hr) InS: - - - - - - - - - - - - - -- Ogg Qup XBP-1/- XBP-1+/+ Tun (0.5ug/ml): O O O.5. 1 2 3 4 O O 0.5 1 2 3 4 (hr) Ins: - - - - - - - - - - - - - - s AAas? as, ? IP:IB: pyIR IP: IR IB: IR FIG. 14B Patent Application Publication Mar. 25, 2010 Sheet 17 of 22 US 2010/0075894 A1 3 sks: 18O s kick S 2 kk 1. 2 O S. k 1 . 6 O O 6 O O O O O 4 8 1216 20 O 4 8. 21620 O 4 8 121620 O 4 8 12 1620 Weeks on Diet Weeks on Diet Weeks on Diet Weeks on Diet FIG. 15A FIG. 15C FIG. 15D 540 540 240 240 .." ck/X sk sk kk 5 3 6 O Yag360 k 1. 6 O sk o 8 O 8 18O 8 O 8 O P ( O O O O O 1530. 6090120 O 1530 6090120 O 1530 60 90120 O 1530 60 90120 Time After Glucose (min) Time After Glucose (min) Time After Insulin (min) Time After Insulin (min) FIG. 15E FIG. 15F FIG. 15G FIG. 15H Patent Application Publication Mar.
Load more

Recommended publications
  • Type 2 Diabetes Mellitus: a Review of Multi-Target Drugs
    Molecules 2020, 25, 1987 1 of 20 Review Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs Angelica Artasensi, Alessandro Pedretti, Giulio Vistoli and Laura Fumagalli * Dipartimento di Scienze Farmaceutiche, University Degli Studi di Milano, 20133 Milano, Italy; [email protected] (A.A.); [email protected] (A.P.); [email protected] (G.V.) * Correspondence: [email protected]; Tel.: +39-02-5031-9303 Academic Editor: Massimo Bertinaria, Derek J. McPhee Received: 01 April 2020; Accepted: 21 April 2020; Published: 23 April 2020 Abstract: Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of population and according to the World Health Organization (WHO) the number of adults living with diabetes is expected to increase. Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90–95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes. In particular, the review considers the main systems directly involved in T2DM or involved in diabetes comorbidities. Agonists acting on incretin, glucagon systems, as well as on peroxisome proliferation activated receptors are considered. Inhibitors which target either aldose reductase and tyrosine phosphatase 1B or sodium glucose transporters 1 and 2 are taken into account. Moreover, with a view at the multi-target approaches for T2DM some phytocomplexes are also discussed. Keywords: diabetes mellitus; type 2 diabetes mellitus; multi-target compounds; multi-target drugs 1.
    [Show full text]
  • Dualism of Peroxisome Proliferator-Activated Receptor Α/Γ: a Potent Clincher in Insulin Resistance
    AEGAEUM JOURNAL ISSN NO: 0776-3808 Dualism of Peroxisome Proliferator-Activated Receptor α/γ: A Potent Clincher in Insulin Resistance Mr. Ravikumar R. Thakar1 and Dr. Nilesh J. Patel1* 1Faculty of Pharmacy, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Gujarat, India. [email protected] Abstract: Diabetes mellitus is clinical syndrome which is signalised by augmenting level of sugar in blood stream, which produced through lacking of insulin level and defective insulin activity or both. As per worldwide epidemiology data suggested that the numbers of people with T2DM living in developing countries is increasing with 80% of people with T2DM. Peroxisome proliferator-activated receptors are a family of ligand-activated transcription factors; modulate the expression of many genes. PPARs have three isoforms namely PPARα, PPARβ/δ and PPARγ that play a central role in regulating glucose, lipid and cholesterol metabolism where imbalance can lead to obesity, T2DM and CV ailments. It have pathogenic role in diabetes. PPARα is regulates the metabolism of lipids, carbohydrates, and amino acids, activated by ligands such as polyunsaturated fatty acids, and drugs used as Lipid lowering agents. PPAR β/δ could envision as a therapeutic option for the correction of diabetes and a variety of inflammatory conditions. PPARγ is well categorized, an element of the PPARs, also pharmacological effective as an insulin resistance lowering agents, are used as a remedy for insulin resistance integrated with type- 2 diabetes mellitus. There are mechanistic role of PPARα, PPARβ/δ and PPARγ in diabetes mellitus and insulin resistance. From mechanistic way, it revealed that dual PPAR-α/γ agonist play important role in regulating both lipids as well as glycemic levels with essential safety issues.
    [Show full text]
  • Comparative Transcriptional Network Modeling of Three PPAR-A/C Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
    Comparative Transcriptional Network Modeling of Three PPAR-a/c Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes Rene´e Deehan1, Pia Maerz-Weiss2, Natalie L. Catlett1, Guido Steiner2, Ben Wong1, Matthew B. Wright2*, Gil Blander1¤a, Keith O. Elliston1¤b, William Ladd1, Maria Bobadilla2, Jacques Mizrahi2, Carolina Haefliger2, Alan Edgar{2 1 Selventa, Cambridge, Massachusetts, United States of America, 2 F. Hoffmann-La Roche AG, Basel, Switzerland Abstract Aims: To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-a/c agonist, aleglitazar, with tesaglitazar (a dual PPAR-a/c agonist) or a combination of pioglitazone (Pio; PPAR-c agonist) and fenofibrate (Feno; PPAR-a agonist) in human hepatocytes. Methods and Results: Gene expression microarray profiles were obtained from primary human hepatocytes treated with EC50-aligned low, medium and high concentrations of the three treatments. A systems biology approach, Causal Network Modeling, was used to model the data to infer upstream molecular mechanisms that may explain the observed changes in gene expression. Aleglitazar, tesaglitazar and Pio/Feno each induced unique transcriptional signatures, despite comparable core PPAR signaling. Although all treatments inferred qualitatively similar PPAR-a signaling, aleglitazar was inferred to have greater effects on high- and low-density lipoprotein cholesterol levels than tesaglitazar and Pio/Feno, due to a greater number of gene expression changes in pathways related to high-density and low-density lipoprotein metabolism. Distinct transcriptional and biologic signatures were also inferred for stress responses, which appeared to be less affected by aleglitazar than the comparators. In particular, Pio/Feno was inferred to increase NFE2L2 activity, a key component of the stress response pathway, while aleglitazar had no significant effect.
    [Show full text]
  • CDR Clinical Review Report for Soliqua
    CADTH COMMON DRUG REVIEW Clinical Review Report Insulin glargine and lixisenatide injection (Soliqua) (Sanofi-Aventis) Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin. Service Line: CADTH Common Drug Review Version: Final (with redactions) Publication Date: January 2019 Report Length: 118 Pages Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • NPY1R-Targeted Peptide-Mediated Delivery of a Dual PPAR&Alpha
    Original Article NPY1R-targeted peptide-mediated delivery of a dual PPARa/g agonist to adipocytes enhances adipogenesis and prevents diabetes progression Stefanie Wittrisch 1, Nora Klöting 2,**, Karin Mörl 1, Rima Chakaroun 2,3, Matthias Blüher 2,3,***, Annette G. Beck-Sickinger 1,* ABSTRACT Objective: PPARa/g dual agonists have been in clinical development for the treatment of metabolic diseases including type 2 diabetes and dyslipidemia. However, severe adverse side effects led to complications in clinical trials. As most of the beneficial effects rely on the compound activity in adipocytes, the selective targeting of this cell type is a cutting-edge strategy to develop safe anti-diabetic drugs. The goal of this study was to strengthen the adipocyte-specific uptake of the PPARa/g agonist tesaglitazar via NPY1R-mediated internalization. 7 34 Methods: NPY1R-preferring peptide tesaglitazar-[F ,P ]-NPY (tesa-NPY) was synthesized by a combination of automated SPPS and manual couplings. Following molecular and functional analyses for proof of concept, cell culture experiments were conducted to monitor the effects on adipogenesis. Mice treated with peptide drug conjugates or vehicle either by gavage or intraperitoneal injection were characterized phenotypically and metabolically. Histological analysis and transcriptional profiling of the adipose tissue were performed. 7 34 Results: In vitro studies revealed that the tesaglitazar-[F ,P ]-NPY conjugate selectively activates PPARg in NPY1R-expressing cells and enhances adipocyte differentiation and adiponectin expression in adipocyte precursor cells. In vivo studies using db/db mice demonstrated that the anti-diabetic activity of the peptide conjugate is as efficient as that of systemically administered tesaglitazar.
    [Show full text]
  • The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
    International Journal of Molecular Sciences Review The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development Fan Hong 1,2, Pengfei Xu 1,*,† and Yonggong Zhai 1,2,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] (P.X.); [email protected] (Y.Z.); Tel.: +86-156-005-60991 (P.X.); +86-10-5880-6656 (Y.Z.) † Current address: Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. Received: 22 June 2018; Accepted: 24 July 2018; Published: 27 July 2018 Abstract: Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
    [Show full text]
  • Thiazolidinedione Drugs Down-Regulate CXCR4 Expression on Human Colorectal Cancer Cells in a Peroxisome Proliferator Activated Receptor Á-Dependent Manner
    1215-1222 26/3/07 18:16 Page 1215 INTERNATIONAL JOURNAL OF ONCOLOGY 30: 1215-1222, 2007 Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor Á-dependent manner CYNTHIA LEE RICHARD and JONATHAN BLAY Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, B3H 1X5, Canada Received October 26, 2006; Accepted December 4, 2006 Abstract. Peroxisome proliferator activated receptor (PPAR) Introduction Á is a nuclear receptor involved primarily in lipid and glucose metabolism. PPARÁ is also expressed in several cancer types, Peroxisome proliferator activated receptors (PPARs) are and has been suggested to play a role in tumor progression. nuclear hormone receptors that are involved primarily in PPARÁ agonists have been shown to reduce the growth of lipid and glucose metabolism (1). Upon ligand activation, colorectal carcinoma cells in culture and in xenograft models. these receptors interact with the retinoid X receptor (RXR) Furthermore, the PPARÁ agonist thiazolidinedione has been and bind to peroxisome proliferator response elements (PPREs), shown to reduce metastasis in a murine model of rectal cancer. leading to transcriptional regulation of target genes. Members Since the chemokine receptor CXCR4 has emerged as an of the thiazolidinedione class of antidiabetic drugs act as important player in tumorigenesis, particularly in the process ligands for PPARÁ (2), as does endogenously produced 15- 12,14 of metastasis, we sought to determine if PPARÁ agonists deoxy-¢ -prostaglandin J2 (15dPGJ2) (3). might act in part by reducing CXCR4 expression. We found In addition to regulation of glucose metabolism, PPARÁ that rosiglitazone, a thiazolidinedione PPARÁ agonist used appears also to be involved in tumorigenesis, although its primarily in the treatment of type 2 diabetes, significantly exact role has yet to be elucidated (4).
    [Show full text]
  • Possible Role of Rivoglitazone Thiazolidine Class of Drug As Dual
    Medical Hypotheses 131 (2019) 109305 Contents lists available at ScienceDirect Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy Possible role of rivoglitazone thiazolidine class of drug as dual-target therapeutic agent for bacterial infections: An in silico study T ⁎ Vidyasrilekha Yele , Niladri Saha, Afzal Azam Md Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Ootacamund, JSS Academy of Higher Education & Research, Mysuru 643001, India ARTICLE INFO ABSTRACT Keywords: Infections due to resistant bacteria are the life-threatening and leading cause of mortality worldwide. The Rivoglitazone current therapy for bacterial infections includes treatment with various drugs and antibiotics. The misuse and ParE over usage of these antibiotics leads to bacterial resistance. There are several mechanisms by which bacteria MurE exhibit resistance to some antibiotics. These include drug inactivation or modification, elimination of antibiotics Docking through efflux pumps, drug target alteration, and modification of metabolic pathway. However, it is difficult to MM-GBSA treat infections caused by resistant bacteria by conventional existing therapy. In the present study binding af- Molecular dynamic simulations fi Anti-bacterial agent nities of some glitazones against ParE and MurE bacterial enzymes are investigated by in silico methods. As evident by extra-precision docking and binding free energy calculation (MM-GBSA) results, rivoglitazone ex- hibited higher binding affinity against both ParE and MurE enzymes compared to all other selected compounds. Further molecular dynamic (MD) simulations were performed to validate the stability of rivoglitazone/4MOT and rivoglitazone/4C13 complexes and to get insight into the binding mode of inhibitor. Thus, we hypothesize that structural modifications of the rivoglitazone scaffold can be useful for the development of an effective antibacterial agent.
    [Show full text]
  • Peroxisome Proliferator-Activated Receptors As Superior Targets to Treat Diabetic Disease, Design Strategies - Review Article
    Review article DOI: 10.4274/tjps.galenos.2021.70105 Peroxisome proliferator-activated receptors as superior targets to treat diabetic disease, design strategies - review article Diyabetik hastalığı tedavi etmek için üstün hedefler olarak peroksizom proliferatör ile aktive edilmiş reseptörler, tasarım stratejileri - inceleme makalesi Mohammed T Qaoud1, Ihab Al-masri2, Tijen Önkol1 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara- Turkey 2Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Al Azhar University, Gaza Strip, Palestine proof Corresponding Author Mohammed T Qaoud, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara-Turkey [email protected] +90 552 634 15 56 https://orcid.org/0000-0002-9563-9493 09.12.2020 31.05.2021 09.06.2021 Abstract Thiazolidinedione (TZD), a class of drugs that are mainly used to control type II diabetes mellitus (T2DM), acts fundamentally as a ligand of peroxisome proliferator-activated receptors (PPARs). Besides activating pathways responsible for glycemic control via enhancing insulin sensitivity and lipid homeostasis, activating PPARs leads to exciting other pathways related to bone formation, inflammation, and cell proliferation. Unfortunately, this diverse effect via activating several pathways may show in some studies adverse health outcomes as osteological, hepatic, cardiovascular, and carcinogenic effects. Thus, an argent demand is present to find and develop new active and potent antiglycemic drugs for the treatment of T2DM. To achieve this goal, the structure of TZD for research is considered as a leading structure domain. This review would guide future research in the design of novel TZD derivatives through highlighting the general modifications conducted to the structure component of TZD scaffold affecting their potency, binding efficacy, and selectivity for the control of type II diabetes mellitus.
    [Show full text]
  • Molecular Modeling Study of Pparγ Agonists: Dehydro-Di-Isoeugenol, Macelignan, Pioglitazone, Netoglitazone, and Rosiglitazone As Antidiabetic Drugs
    International Journal of Chemistry; Vol. 6, No. 2; 2014 ISSN 1916-9698 E-ISSN 1916-9701 Published by Canadian Center of Science and Education Molecular Modeling Study of PPARγ Agonists: Dehydro-Di-Isoeugenol, Macelignan, Pioglitazone, Netoglitazone, and Rosiglitazone as Antidiabetic Drugs Nyi Mekar Saptarini1, Febrina Amelia Saputri1 & Jutti Levita1 1 Faculty of Pharmacy, Padjadjaran University, West Java, Indonesia Correspondence: Nyi Mekar Saptarini, Faculty of Pharmacy, Padjadjaran University, Jl. Raya Bandung-Sumedang Km.21 Jatinangor Sumedang, West Java 45363, Indonesia. Tel: 62-815-607-8248. Fax: 62- 227-796-200. E-mail: [email protected] Received: February 23, 2014 Accepted: April 2, 2014 Online Published: April 14, 2014 doi:10.5539/ijc.v6n2p48 URL: http://dx.doi.org/10.5539/ijc.v6n2p48 Abstract The peroxisome proliferator-activated receptors (PPARs) are ligand-activated trasncription factors belonging to the nuclear receptor family. The objective of this study is to analyze the molecular aspects of PPARγ agonists which used to design of new antidiabetic drugs. The analysis method was comparing the interactions of ligands in the ligand binding domain of the PPARγ. This analysis showed that most known agonists of PPARγ interacted via hydrogen bond with Tyr473. Pioglitazone showed three hydrogen bonds with His323 and Tyr473. Netoglitazone showed four hydrogen bonds with Ser289, His323, His449, and Tyr473. Rosiglitazone showed five hydrogen bonds with Ser289, His323, His449, and Tyr473. AZ72, an agonist of PPARα and γ showed five hydrogen bonds with Ser289, His323, His449, and Tyr473. Molecular modeling was performed by redocking pioglitazone and rosiglitazone using AutoDock Vina. Docking showed that both pioglitazone (Ki 0.22 μM) and rosiglitazone (Ki 0.70 μM) occupied their origin sites and interacted with Tyr473.
    [Show full text]
  • Oral Anti-Diabetic Agents-Review and Updates
    British Journal of Medicine & Medical Research 5(2): 134-159, 2015, Article no.BJMMR.2015.016 ISSN: 2231-0614 SCIENCEDOMAIN international www.sciencedomain.org Oral Anti-Diabetic Agents-Review and Updates Patience O. Osadebe1, Estella U. Odoh2 and Philip F. Uzor1* 1Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, 410001, Nigeria. 2Department of Pharmacognosy and Environmental Medicine, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, 410001, Nigeria. Authors’ contributions Author POO designed the study, participated in the literature search. Author EUO participated in designing the work and in searching the literature. Author PFU participated in designing the work, searched the literature and wrote the first draft of the manuscript. All authors read and approved the final manuscript. Article Information DOI:10.9734/BJMMR/2015/8764 Editor(s): (1) Mohamed Essa, Department of Food Science and Nutrition, Sultan Qaboos University, Oman. (2) Franciszek Burdan, Experimental Teratology Unit, Human Anatomy Department, Medical University of Lublin, Poland and Radiology Department, St. John’s Cancer Center, Poland. Reviewers: (1) Anonymous, Bushehr University of Medical, Iran. (2) Anonymous, Tehran University of Medical Sciences, Iran. (3) Anonymous, King Fahad Armed Forces Hospital, Saudi Arabia. (4) Awadhesh Kumar Sharma, Mlb Medical College, Jhansi, UP, India. Peer review History: http://www.sciencedomain.org/review-history.php?iid=661&id=12&aid=5985 Received 30th December 2013 Review Article Accepted 13th March 2014 Published 8th September 2014 ABSTRACT Diabetes is a chronic metabolic disorder with high mortality rate and with defects in multiple biological systems. Two major types of diabetes are recognized, type 1 and 2 with type 2 diabetes (T2D) being by far the more prevalent type.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]